Company / Interest Expense
AXIM BIOTECHNOLOGIES, INC. Interest Expense History
FY2015-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Interest Expense
$140.0K
FY2023
5-year range
$140.0K / $456.1K
FY2019-FY2023
Trend
-46.5%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $456,063 to $140,000 over the past 5 years.
Based on SEC 10-K filings.
$140,000 in FY2023 with a 5-year CAGR of -21.0%.
Improved from $456,063 to $140,000 over the past 5 years.
Interest Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -21.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -21.0%, indicating a declining trend.
- In FY2023, interest expense decreased 46.5% year-over-year.
- Peak interest expense was recorded in FY2018.
- Lowest interest expense in the period was in FY2015.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -18.18 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Interest ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2023 | $140.0K | -46.5% |
| FY2022 | $261.5K | -42.7% |
| FY2018 | $456.1K | +44.8% |
| FY2017 | $315.0K | +14.2% |
| FY2016 | $275.7K | +538.0% |
| FY2015 | $43.2K | - |
| FY2013 | - | - |
| FY2012 | - | - |
| FY2011 | - | - |
As of FY2023 · SEC 10-K · Updated Jun 29, 2026